Child-Parent Familial Hypercholesterolemia Screening

NCT ID: NCT04529967

Last Updated: 2025-05-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

15000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-01

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Child-parent screening for familial hypercholesterolemia has been proposed to identify children and their parent who are carrier of mutations and with high risk for inherited premature coronary artery disease. The investigators assessed the efficacy and feasibility of such screening in primary care practice.

key scientific questions:

1. The 95th and 99th percentile of finger blood TC in children of 2 years old.
2. Mutations that contribute to high TC status ( serum TC \>99th percentiles) compared with international FH48 panel for FH genetic screening.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Familial hypercholesterolemia (FH) is an inherited condition resulting in high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of premature coronary artery disease in men and women. Child-parent screening for familial hypercholesterolemia has been proposed to identify persons who are carriers of FH mutations and with high risk for inherited premature coronary artery disease. The investigators will conduct a cross-sectional community-based screening in children of 2 years old to detect FH children cases using finger blood TC test first and followed by serum TC test and mutation test, and to identify and diagnose their affected parents. This study aims to established the child-parent screening program and technique issues for early diagnosis of familial hypercholesterolemia families for future early intervention.

Child-parent screening strategy in our study consists three steps: i. Capillary blood total cholesterol test of children aged around 2 years; ii. re-test for children with cholesterol\>95th percentile in the first step; iii. WES (whole exome sequencing) test for \>P99 in the first two steps. iV: TC test and mutation test to the parents of the child FH cases. The investigators will determine FH families based on the program. Children's Hospital of Fudan University will provide treatment further.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Familial Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no interventions

it is a observational study, do not have interventions.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Receive routine child care
* aged 1 - 3 years old ( date of investigate minus date of birth)

Exclusion Criteria

* It is up to the researcher to decide whether it is suitable to participate in this research
Minimum Eligible Age

1 Year

Maximum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Children's Hospital of Fudan University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

LIling Qian, Master

Role: STUDY_DIRECTOR

Children's Hospital of Fudan University

Rui Dong, MD

Role: STUDY_DIRECTOR

Children's Hospital of Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Anhui Provincial Children's Hospital

Hefei, Anhui, China

Site Status RECRUITING

Qidong Women and Children Hospital

Qidong, Jiangsu, China

Site Status RECRUITING

Weili Yan

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Shanxi Provincial Children's Hospital

Taiyuan, Shanxi, China

Site Status RECRUITING

Chongqin Medical University Affiliated Children's Hospital

Chongqing, Sichuan, China

Site Status RECRUITING

Urumqi Children's Hospital

Ürümqi, Xinjiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Weili Yan

Role: CONTACT

+86 21 64931215

Fang Liu, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Haipeng Liu

Role: primary

Jun Shen

Role: primary

YI Zhang, PhD

Role: primary

Lixia Bai

Role: primary

Xiaohua Liang

Role: primary

Wenping Cai

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHFD-2020007

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pediatric Parenting Support in Flint
NCT03945552 ACTIVE_NOT_RECRUITING NA
Healthy Baby Healthy Mother Toolkit
NCT06594419 RECRUITING NA
Newborn Health Information Study
NCT00820677 COMPLETED NA